share_log

新华医疗获华安证券买入评级,历久弥坚,老牌国企绽放新活力

JRJ Finance ·  Jul 3 09:57

7月3日,新华医疗获华安证券买入评级,近一个月新华医疗获得1份研报关注。

研报预计公司2024-2026年营业收入有望分别实现110/120/130亿元,同比增长9.5%/9.2%/8.5%;归母净利润分别实现8.3/10.5/12.7亿元,同比增长27.0%/26.8%/20.2%。研报认为,公司利润释放主要来自大股东主导下的结构调整和降本增效,看好公司国内高毛利耗材类产品的持续放量和占比提升,看好公司医疗器械和制药装备出海。

风险提示:采购政策带来的波动,医疗器械、制药装备销售不及预期。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment